#USA #New York #securities claims #QuidelOrtho #SueWallSt

QuidelOrtho Shareholder Investigation

In recent developments, QuidelOrtho Corporation (NASDAQ: QDEL) has found itself under scrutiny following a significant drop in its revenue from China. A staggering 45% decline in revenue for the third quarter of 2026 has raised eyebrows amongst investors and has resulted in a share price dip of approximately 14% upon public disclosure of the third-quarter results. This decline has prompted SueWallSt to notify shareholders about a potential investigation regarding undisclosed risks associated with regulatory pricing in China.

Background of the Issue

QuidelOrtho's revenue drop can be attributed to changes in pricing and an overall destocking of products among distributors in China. The company's quarterly report from May 2026 had previously indicated that the impact of China's volume-based procurement program (VBP) would likely not have a material effect on total annual revenue. However, the sharp decline reported later contradicts this assertion and has led to allegations that the company may have misrepresented the risks involved.

VBP is a government-managed tender system that controls pricing for medical products sold to public hospitals in China, which can create significant fluctuations in revenue for companies involved. Six months after showing confidence in its revenue projections, QuidelOrtho's unexpected reporting shows that the company's assumptions may have been overly optimistic or not adequately disclosed to investors.

Details of the Investigation

Presently, eligible shareholders who have incurred losses following the disappointing Q3 results are encouraged to submit their information for a free evaluation of their potential claims. These claims can be directed to the firm's attorney, Joseph E. Levi, who is managing the securities investigation on behalf of affected investors.

SueWallSt, bolstered by the expertise of Levi Korsinsky LLP, a nationally recognized securities litigation firm, has successfully championed various high-stakes cases and aggressively advocates for investors’ rights. They highlight that investors who bought shares at inflated prices may be entitled to recover their losses through appropriate legal channels.

Key Investor Questions Addressed

The investigation has raised several pertinent questions among investors:

• - Who is eligible for participation? Any investor who purchased QuidelOrtho stocks or associated securities and suffered losses could qualify for participation in the ongoing investigation.
• - What led to the stock decline? After the revelation of a 45% reduction in Chinese revenue, QuidelOrtho's stock experienced a significant drop in value.
• - Which statements are under investigation? The accuracy of QuidelOrtho’s statements surrounding the potential risks posed by the VBP program is being evaluated for possible misleading elements.
• - What actions should investors take now? Collecting documentation, such as brokerage records reflecting purchase dates and quantities, is recommended for investors looking to participate in the investigation and potential recovery.

Importantly, no initial costs are associated with submitting information for evaluation. If it leads to further legal action, any fees incurred will typically be contingent upon the outcome of the case and require court approval.

Conclusion

As QuidelOrtho navigates these turbulent waters, affected investors are encouraged to stay informed and proactive in assessing their losses. The ongoing investigation led by SueWallSt aims to ensure that shareholders receive any compensation they may be entitled to due to potential securities law violations by the company. This situation serves as a reminder of the complexities and risks inherent in investing, particularly in industries subject to regulatory landscapes.

For additional details or to submit your investment information, contact SueWallSt at the provided channels to ensure that your interests are represented as this situation unfolds.